September 7, 2023
6:30 pm - 8:30 pm
This will be a promotional speaker program for nurses and advanced practitioners, with a focus on practical considerations in management of certain patients with pretreated mTNBC and HR+/HER2 metastatic breast cancer receiving TRODELVY.
This is a non-CME/CE Session
TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:
- Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
- Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Thursday, September 7, 2023 6:30 PM
Check-in begins at 6:00 pm
LESLIE GIANG, PharmD
Senior Medical Scientist
Chamberlain’s Steak and Chop House
5330 Belt Line Road
Dallas, Texas 75254
Scholarship Donation Fee
Please, NO REFUNDS OR EXCHANGES – these funds are for the scholarship fund and are eligible for tax-deductions. The funds go towards the funds to support our pharmacy students!!
Presentation from Gilead
Installation of officers
Tuesday, September 5, 2023